Prelude Therapeutics Inc (PRLD) FinancialsPRLDPrelude Therapeutics Inc

Evaluating the bottom line, Prelude Therapeutics Incorporated maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -270.93%, while the net margin is -244.06%. These profitability ratios, combined with a Return on Equity (ROE) of -57.73%, provide a clear picture of how effectively PRLD converts its operational activities into shareholder value.

In the context of the broader market, PRLD competes directly with industry leaders such as AGEN and BNTC. With a market capitalization of $325.58M, it holds a leading position in the sector. When comparing efficiency, PRLD's gross margin of 100.00% stands against AGEN's 100.00% and BNTC's N/A. Such benchmarking helps identify whether Prelude Therapeutics Incorporated is trading at a premium or discount relative to its financial performance.

Prelude's gross margin is consistently high at 100% for the last reported quarters, indicating strong profitability potential on its revenue. However, net income remains negative, with a recent net income of -10,385,000 USD in Q1 2026.